A Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia
- Conditions
- Schizophrenia
- Registration Number
- NCT00089869
- Lead Sponsor
- Eli Lilly and Company
- Brief Summary
Study of a medication for the treatment of Schizophrenia in patients who are already taking Abilify, Risperdal, Seroquel, Zyprexa
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
- Must have a clinical diagnosis of Schizophrenia
- Must be at least 18 years of age and not older than 55 years of age
- Must have been stable on a dose of Abilify, Risperdal, Seroquel, or Zyprexa for the past 8 weeks
- Women of childbearing potential must be using a medically accepted means of contraception
- Must be able to swallow capsules
- Has serious health problems other than Schizophrenia
- Takes an antidepressant for depression
- Takes insulin for diabetes
- Have a history of alcohol or drug dependence (except for nicotine and caffeine) within the past 6 months
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (3)
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician.
🇺🇸Chula Vista, California, United States
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
🇺🇸Irving, Texas, United States
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
🇺🇸San Antonio, Texas, United States